首页|期刊导航|临床传统医学和药理学(英文)|匙羹藤(Gymnema sylvestre)联合镁与维生素D3对2型糖尿病患者血糖控制效果的疗效评价:一项前瞻性、开放标签、单臂临床研究及潜在机制探讨

匙羹藤(Gymnema sylvestre)联合镁与维生素D3对2型糖尿病患者血糖控制效果的疗效评价:一项前瞻性、开放标签、单臂临床研究及潜在机制探讨OA

Assessment of Gymnema sylvestre in association with magnesium and vitamin D3 on glycemic control in type 2 diabetes mellitus:A prospective,open-label,single-arm study with possible mechanistic insights

中文摘要英文摘要

背景:2型糖尿病(T2DM)是一种以胰岛素抵抗和葡萄糖调节功能障碍为特征的慢性代谢性疾病.医疗产品、服务及可靠信息的可及性增加了疾病诊疗的难度,亟需经济有效的干预措施.在此背景下,辅助性措施(即营养保健品制剂)因其能够提高胰岛素敏感性并辅助糖尿病综合诊疗而备受关注.目的:该研究旨在评估一种营养保健品制剂对T2DM患者的安全性和有效性.研究测定了包括空腹血糖(FPG)、餐后血糖(PPG)和糖化血红蛋白(HbA1c)在内的代谢指标,并评估了生活质量(QoL)及糖尿病相关症状的改善情况.方法:该前瞻性、开放标签研究招募了 18至65岁、确诊为T2DM的男女受试者.受试者在常规抗糖尿病治疗的基础上,每日服用两粒该制剂,持续12周.数据采用统计学工具进行分析.研究遵循《赫尔辛基宣言》(DoH)及国际人用药品注册技术协调会-药物临床试验质量管理规范(ICH-GCP),已获得赛克鲁帕医院机构伦理委员会批准(批准号:ECR/1350/Inst/MH/2020;2024年6月7日),并在印度临床试验(CTRI)完成注册(注册号:CTRI/2024/06/068889;2024年6月6日,注册链接:https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=MTA1NTc4&Enc=&userName=).结果:30 名受试者完成了研究,未报告任何不良事件.在第12周时,与基线相比,HbA1c、FPG和PPG水平均显著降低.受试者的生活质量评分也显著提高,嗜糖欲望降低.结论:研究结果表明,标准化匙羹藤叶提取物联合镁、维生素D3的制剂安全可靠,可改善T2DM患者的血糖控制及整体代谢健康状况.通过提高胰岛素敏感性并降低嗜糖欲望,该制剂有望成为传统糖尿病管理策略中一种经济实惠且耐受性良好的辅助治疗手段.

Background:Type 2 Diabetes Mellitus(T2DM)is a chronic metabolic disorder characterized by insulin resistance and impaired glucose regulation.Unequal access to healthcare products,services,and reliable information com-plicates effective disease management,underscoring the urgent need for affordable,supportive interventions.In this context,adjunctive strategies,i.e.,nutraceutical formulations,are gaining interest for their potential to enhance insulin sensitivity and support overall diabetes management. Objective:This study aimed to evaluate the safety and efficacy of a nutraceutical formulation in individuals with T2DM.Study determines metabolic parameters such as fasting plasma glucose(FPG),postprandial plasma glucose(PPG),and glycated hemoglobin(HbA1c)levels including quality-of-life(QoL)and diabetes-related symptom management. Methods:This prospective,open-label study enrolled male and female participants aged 18-65 years with es-tablished T2DM.Participants received two capsules of the formulation daily for 12 weeks in addition to their standard antidiabetic therapy.Data were analysed with statistically tools. The study was conducted in accordance with the Declaration of Helsinki(DoH)and International Council for Harmonisation-Good Clinical Practice(ICH-GCP)guidelines,with approval from the Sai Krupa Hospital Institutional Ethics Committee(Ref.No.ECR/1350/Inst/MH/2020;dated June 07,2024)and registration in the Clinical Trials Registry of India(CTRI)(URL:https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=MTA1NTc4&Enc=&userName=,Reg.No.:CTRI/2024/06/068889;dated June 06,2024). Results:Thirty participants completed the study without any reported adverse events.At Week 12,significant reductions were observed in HbA1c,FPG,and PPG levels compared with the baseline.Participants also demon-strated significant improvements in QoL scores and a reduction in sugar cravings. Conclusion:The findings indicate that the combination of magnesium,vitamin D3 and a standardized leaf extract of Gymnema sylvestre is safe and leads to an improvement in glycemic control and overall metabolic well-being in individuals with T2DM.By improving insulin sensitivity and reducing sugar cravings,this formulation shows promise as an affordable and well-tolerated adjunct to conventional diabetes management strategies.

Neelesh Kumar Nema;Smitha Sarojam;Keerthana K;Chandu Devanpally;Varghese Jacob

C.V.J.Creative Centre,Bio-Ingredients,Synthite Industries Pvt.Ltd.,Kadayiruppu 682311,Kerala,IndiaC.V.J.Creative Centre,Bio-Ingredients,Synthite Industries Pvt.Ltd.,Kadayiruppu 682311,Kerala,IndiaZenriva Brands Pvt.Ltd,Ernakulam 682 016,Kerala,IndiaArdent Clinical Research Services Pvt.Ltd.,Pune 411 006,Maharashtra,IndiaC.V.J.Creative Centre,Bio-Ingredients,Synthite Industries Pvt.Ltd.,Kadayiruppu 682311,Kerala,India

糖尿病糖化血红蛋白嗜甜胰岛素营养保健品草本植物

DiabetesHbA1cSugar cravingInsulinNutraceuticalHerbs

《临床传统医学和药理学(英文)》 2026 (2)

33-48,16

Synthite Industries Pvt.Ltd.,the manufacturer of Gymne-Mag D®,provided financial support for the conduct of this clinical trial.The study was operationally managed by Ardent Clinical Research Services Pvt.Ltd.,which functioned as the designated clinical research organization.No governmental or public-sector funding was received for the design,execution,analysis,or reporting of this study.The sponsors had no un-due influence on the scientific integrity or interpretation of the study outcomes.

10.1016/j.ctmp.2026.200286

评论